Literature DB >> 28148797

Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

Alba Grifoni1, Michael Angelo1, John Sidney1, Sinu Paul1, Bjoern Peters1, Aruna D de Silva1,2, Elizabeth Phillips3, Simon Mallal3, Sean A Diehl4, Jason Botten4, Jonathan Boyson4, Beth D Kirkpatrick4, Stephen S Whitehead5, Anna P Durbin6, Alessandro Sette1, Daniela Weiskopf7.   

Abstract

A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region (rDEN2Δ30) has previously been established for use in a controlled human DENV challenge model. To evaluate if this model is appropriate for the derivation of correlates of protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular immune response to this challenge strain to the response induced by natural infection. To achieve this, we predicted HLA class I- and class II-restricted peptides from rDEN2Δ30 and used them in a gamma interferon enzyme-linked immunosorbent spot assay to interrogate CD8+ and CD4+ T cell responses in healthy volunteers infected with rDEN2Δ30. At the level of CD8 responses, vigorous ex vivo responses were detected in approximately 80% of donors. These responses were similar in terms of the magnitude and the numbers of epitopes recognized to the responses previously observed in peripheral blood mononuclear cells from donors from regions where DENV is hyperendemic. The similarity extended to the immunodominance hierarchy of the DENV nonstructural proteins, with NS3, NS5, and NS1 being dominant in both donor cohorts. At the CD4 level, the responses to rDEN2Δ30 vaccination were less vigorous than those to natural DENV infection and were more focused on nonstructural proteins. The epitopes recognized following rDEN2Δ30 infection and natural infection were largely overlapping for both the CD8 (100%) and CD4 (85%) responses. Finally, rDEN2Δ30 induced stronger CD8 responses than other, more attenuated DENV isolates.IMPORTANCE The lack of a known correlate of protection and the failure of a neutralizing antibody to correlate with protection against dengue virus have highlighted the need for a human DENV challenge model to better evaluate the candidate live attenuated dengue vaccines. In this study, we sought to characterize the immune profiles of rDEN2Δ30-infected subjects and to compare the profiles with those for subjects from areas where DENV is hyperendemic. Our data demonstrate that T cell responses to rDENV2Δ30 are largely similar to those to natural infection in terms of specificity, highlighting that the response to this virus in humans is appropriate as a model for the T cell response to primary DENV2 infection.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  T cells; dengue virus; human challenge model; vaccine

Mesh:

Substances:

Year:  2017        PMID: 28148797      PMCID: PMC5375662          DOI: 10.1128/JVI.02133-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  EPIDEMIOLOGY. Countering the Zika epidemic in Latin America.

Authors:  Neil M Ferguson; Zulma M Cucunubá; Ilaria Dorigatti; Gemma L Nedjati-Gilani; Christl A Donnelly; Maria-Gloria Basáñez; Pierre Nouvellet; Justin Lessler
Journal:  Science       Date:  2016-07-14       Impact factor: 47.728

2.  Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga.

Authors:  D J Gubler; D Reed; L Rosen; J R Hitchcock
Journal:  Am J Trop Med Hyg       Date:  1978-05       Impact factor: 2.345

3.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

Review 4.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

5.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

6.  MAFFT multiple sequence alignment software version 7: improvements in performance and usability.

Authors:  Kazutaka Katoh; Daron M Standley
Journal:  Mol Biol Evol       Date:  2013-01-16       Impact factor: 16.240

7.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

Review 8.  Immune correlates for dengue vaccine development.

Authors:  Anon Srikiatkhachorn; In-Kyu Yoon
Journal:  Expert Rev Vaccines       Date:  2015-11-24       Impact factor: 5.217

9.  Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.

Authors:  Joseph E Blaney; Christopher T Hanson; Kathryn A Hanley; Brian R Murphy; Stephen S Whitehead
Journal:  BMC Infect Dis       Date:  2004-10-04       Impact factor: 3.090

10.  The immune epitope database (IEDB) 3.0.

Authors:  Randi Vita; James A Overton; Jason A Greenbaum; Julia Ponomarenko; Jason D Clark; Jason R Cantrell; Daniel K Wheeler; Joseph L Gabbard; Deborah Hix; Alessandro Sette; Bjoern Peters
Journal:  Nucleic Acids Res       Date:  2014-10-09       Impact factor: 16.971

View more
  12 in total

Review 1.  Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

Review 2.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

3.  Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination.

Authors:  Alessandro Sette; Alba Grifoni; Hannah Voic; Rory D de Vries; John Sidney; Paul Rubiro; Erin Moore; Elizabeth Phillips; Simon Mallal; Brittany Schwan; Daniela Weiskopf
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

4.  Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model.

Authors:  John P Hanley; Huy A Tu; Julie A Dragon; Dorothy M Dickson; Roxana Del Rio-Guerra; Scott W Tighe; Korin M Eckstrom; Nicholas Selig; Samuel V Scarpino; Stephen S Whitehead; Anna P Durbin; Kristen K Pierce; Beth D Kirkpatrick; Donna M Rizzo; Seth Frietze; Sean A Diehl
Journal:  Nat Commun       Date:  2021-05-24       Impact factor: 17.694

5.  Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas.

Authors:  Alba Grifoni; Michael A Angelo; Benjamin Lopez; Patrick H O'Rourke; John Sidney; Cristhiam Cerpas; Angel Balmaseda; Cassia G T Silveira; Alvino Maestri; Priscilla R Costa; Anna P Durbin; Sean A Diehl; Elizabeth Phillips; Simon Mallal; Aruna D De Silva; Godwin Nchinda; Celine Nkenfou; Matthew H Collins; Aravinda M de Silva; Mei Qiu Lim; Paul A Macary; Filippo Tatullo; Tom Solomon; Vijaya Satchidanandam; Anita Desai; Vasanthapram Ravi; Josefina Coloma; Lance Turtle; Laura Rivino; Esper G Kallas; Bjoern Peters; Eva Harris; Alessandro Sette; Daniela Weiskopf
Journal:  Front Immunol       Date:  2017-10-13       Impact factor: 7.561

6.  Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.

Authors:  Usha K Nivarthi; Huy A Tu; Matthew J Delacruz; Jesica Swanstrom; Bhumi Patel; Anna P Durbin; Stephen S Whitehead; Kristen K Pierce; Beth D Kirkpatrick; Ralph S Baric; Ngan Nguyen; Daniel E Emerling; Aravinda M de Silva; Sean A Diehl
Journal:  EBioMedicine       Date:  2019-03-08       Impact factor: 8.143

Review 7.  Human T Cell Response to Dengue Virus Infection.

Authors:  Yuan Tian; Alba Grifoni; Alessandro Sette; Daniela Weiskopf
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

8.  Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses.

Authors:  Alba Grifoni; Eugene Moore; Hannah Voic; John Sidney; Elizabeth Phillips; Ramesh Jadi; Simon Mallal; Aruna D De Silva; Aravinda M De Silva; Bjoern Peters; Daniela Weiskopf; Alessandro Sette
Journal:  Front Immunol       Date:  2019-07-05       Impact factor: 7.561

9.  Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.

Authors:  Emily N Gallichotte; Thomas J Baric; Boyd L Yount; Douglas G Widman; Anna Durbin; Steve Whitehead; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2018-02-26       Impact factor: 6.823

Review 10.  Memory T Cells in Flavivirus Vaccination.

Authors:  Guangyu Li; Cody Teleki; Tian Wang
Journal:  Vaccines (Basel)       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.